FIRAZYR General Drug Use-Results Survey (Japan)
About the study
The objectives of this survey are to collect data to report the safety and efficacy of Firazyr (Icatibant acetate) in the post-marketing phase in participants diagnosed with Hereditary Angioedema (HAE).
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
Hereditary angioedema (HAE) participants in Japan who receive FIRAZYR for first time in the real world clinical setting.
EXCLUSION CRITERIA
Exclusion Criteria
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Hereditary Angioedema (HAE)
Participants needed
304
Est. Completion Date
Jan 31, 2024
Treatment type
Observational
Sponsor
Takeda
ClinicalTrials.gov identifier
NCT04057131
Study number
SHP667-401
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?